Список литературы

Budinger L. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls / Budinger L., Borradori L., Yee C. et al. // J. Clin. Invest. – 1998. – Vol. 102. – p. 2082-2089;
Kirtschig G. Interventions for bullous pemphigoid / Kirtschig G., Middleton P., Bennett C. et al. // Cochrane Database Syst. Rev. – 2010. – 10. – CD002292;
Parker S.R. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States / Parker S.R., Dyson S., Brisman S. et al. // J Am Acad Dermatolю – 2008. – 59 (4). – p. 582–588;
Schmidt E. Pemphigoid diseases / Schmidt E., Zillikens D. // Lancet. – 2013. – 381. – p.320–332;
Gul U. Bullous pemphigoid associated with breast carcinoma / Gul U., Kilic A., Demirel O. et al. // Eur. J. Dermatol. – 2006. – Vol. 16. – p. 581-582;
Iranzo P. Bullous pemphigoid associated with mantle cell lymphoma / Iranzo P., Lopez I., Robles M.T. et al. // Arch. Dermatol. – 2004. – Vol. 140. – p. 1496-1499;
Mabrouk D. Association between cancer and immunosuppressive therapy – analysis of selected studies in pemphigus and pemphigoid / Mabrouk D., Gürcan H.M., Keskin D.B. et al. // Ann. Pharmacother. – 2010. – Vol. 44. – N 11. – p. 1770–1776;
Теплюк Н. П. Паранеопластический буллезный пемфигоид Левера при раке яичников и раке левой молочной железы IIа стадии / Теплюк Н. П., Котельникова Л. А., Грабовская О. В. с соавт. // Российский журнал кожных и венерических болезней. – 2013. - № 4. – с. 10 – 14;
Теплюк Н. П. Буллезный пемфигоид Левера как паранеопластический процесс / Теплюк Н. П., Алтаева А. А., Белоусова Т. А. с соавт. // Российский журнал кожных и венерических болезней. – 2012. - №4. – С. 5-10;
Lo Schiavo A. Bullous pemphigoid: Etiology, pathogenesis, and inducing factors: Facts and controversies / Lo Schiavo A., Ruocco E., Brancaccio G. et al. // Clin Dermatol. – 2013. – 31. – р.391–399;
Laffitte E. Bullous pemphigoid: clinical features, diagnostic markers and immunopathogenic mechanisms / Laffitte E., Borradori L. // InbookAutoimmune diseases of the skin; ed. Michel Hertl. – SpringerWienNewYork. – 2005. – p. 71-93;
Castanet J. Formescliniquesatypiques des pemphigoidesbulleuses / Castanet J., Lacour J.-P., Ortone J.-P. // Ann. Dermatol. Venereoi. – 1990. – Vol. 117. – p. 73-82;
Nguyen V.T. Classification, clinical manifestations and immunopathological mechanism of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome / Nguyen V.T., Ndoye A., Bassler K.D et al. // Arch. Dermatol. – 2001. – Vol. 137. – p. 193-206;
Joly P. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study / Joly P., Roujeau J.C., Benichou J. et al. // J Invest Dermatol. – 2009. – 129 (7). – р.1681–1687;
Cozzani E Cutaneous Immunology group of SIDeMaST. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines // Cozzani E., Marzano A.V., Caproni M. et al // EDF/EADV guidelines. – 2018. - 153 (3). - 305-315;
Haili S.M. Clinical, histological and immunological studies in 50 patients with bullous pemphigoid / Haili S.M., Barnetson R.StC., Gawkrodger D.J. et al // Dermatologica. - 176:6-17 (1988);
Белецкая Л.В. Меченые антитела в номральной и патологической морфологии (атлас) / Белецкая Л.В., Махнева Н.В. – Москва: МНПИ, 2000, - 111 с.;
Махнева Н.В. Иммунопатологические аспекты аутоиммунных буллезных дерматозов / Махнева Н.В., Белецкая Л.В. – Palmarium Academic Publishing, 2012, - 408 c.;
Konig A. Heterogeneity of severe dystrophic epidermolysis bullosa: overexpression of collagen VII by cutaneous cells from a patient with mutilating disease / Konig A., Winberg J.O., Gedde-Dahl T. et al // J Invest Dermatol. - 102 (1994). - pp. 155-159;
Yang B. Accuracy of indirect immunofluorescence on sodium chloride-split skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita / Yang B., Wang C., Chen S. et al // Indian J Dermatol Venereol Leprol. – 2011. - Nov-Dec. - 77(6):677-82. - doi: 10.4103/0378-6323.86479;
Sardy M. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid / Sardy M., Kostaki D., Varga R. et al // J Am Acad Dermatol. – 2013. - Nov;69(5):748-753. - doi: 10.1016/j.jaad.2013.07.009;
Murrell D.F. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts / Murrell D.F., Daniel B.S., Joly P. et al. // J Am Acad Dermatol. – 2012. – 66. – р. 479–485;
Feliciani C. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology / Feliciani C., Joly P., Jonkman M.F. et al. // Br J Dermatol. – 2015. – 172. – р. 867–877;
Joly P. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid / Joly P., Roujeau J.C., Benichou J. et al. // N Engl J Med. – 2002. - 346 (5). – р.321–327;
Roujeau J.C. Plasma exchange in bullous pemphigoid / Roujeau J.C., Guillaume J.C., Morel P. et al. // Lancet. – 1984. - 2 (8401). – р. 486–488;
Murrell D.F. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts / Murrell D.F., Daniel B.S., Joly P. et al. // J Am Acad Dermatol. – 2012. – 66. – р. 479–485;
Morel P. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study / Morel P., Guillaume J.C. // Ann Dermatol Venereol. – 1984. - 111 (10). – р. 925–928;
Beissert S. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid / Beissert S., Werfel T., Frieling U. et al. // Arch Dermatol. – 2007. - 143 (12). – р.1536–1542;
Guillaume J.C. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid / Guillaume J.C., Vaillant L., Bernard P. et al. // Arch Dermatol. – 1993. - 129 (1). – р. 49–53;
Du-Thanh A. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study / Du-Thanh A., Merlet S., Maillard H. et al. // Br J Dermatol 2011. - 165 (6). – р.1337–1343;
Heilborn J.D. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid / Heilborn J.D., Ståhle-Bäckdahl M., Albertioni F. et al. // J Am Acad Dermatol. – 1999. – 40. – р.741–749;
Gual A. Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients / Gual A., Iranzo P., Mascaro J.M. // J Eur Acad Dermatol Venereol. – 2014. – 28. – р.814–818;
Br J Dermatol. 2015 Apr;172(4):867-77. doi: 10.1111/bjd.13717. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venerology;
Le Roux-Villet C. Role of the nurse in care of bullous pemphigoid / Le Roux-Villet C., Prost-Squarcioni C., Oro S. et al. // Rev Infirm. – 2010. – 160. – р. 38–40;
Venning V.A. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012 / Venning V.A., Taghipour K., Mohd Mustapa M.F. et al. // Br J Dermatol. – 2012. – 167. – р.1200–1214;
Милявский А.И. Эффективность мирамистина в дерматовенерологии / Милявский А.И., Кривошеин Ю.С., Логадырь Т.А. с саовт. // Вестн. Дерматол. Венерол. – 1996. - (2). – с.67–69;
Привольнев В.В. Основные принципы местного лечения ран и раневой инфекции / Привольнев В.В., Каракулина Е.В. // Клин микробиол антимикроб химиотер. – 2011. – 13(3). – с.214–222.
Приказ Министерства здравоохранения Российской Федерации от 24 декабря 2012 г. № 1484н "Об утверждении стандарта первичной медико-санитарной помощи при буллезном пемфигоиде"